Matthew Tucker
@Tucker_MatthewD
Followers
214
Following
1K
Media
11
Statuses
78
Alabama Oncology (Grandview Cancer Center). Previously @VUMCHemOnc, @IMresidencyDuke. Views expressed here are my own.
Joined May 2020
Our paper on the baseline neutrophil-to-eosinophil ratio and response to nivo/ipi in patients with mRCC is out now! @VUMC_Cancer, @VUMCHemOnc, @DukeCancer, @DukeGuCancer #kidneycancer, #biomarkers
https://t.co/imRJTcZxFR 1/8
biomarkerres.biomedcentral.com
Background The identification of biomarkers to select patients with metastatic renal cell carcinoma (mRCC) most likely to respond to combination immunotherapy (IO) is needed. We sought to investigate...
1
5
24
Updated IO combo table after #ASCO2023 IO/TKI presentations. VEGF tx provides early disease control while Ipi provides durability. We need a way to harness the benefits of both approaches. @montypal @DrChoueiri @tompowles1 @motzermd @HHammersMD
2
98
248
Please stop by our biomarker-driven OPTIC RCC Trial-in-Progress Poster (TPS 742) lead by @brian_rini @DrScottHaake @katy_beckermann, Anupama Reddy ,Yu Shyr @KimrynRathmell @montypal @TiansterZhang @MosheOrnsteinMD @PBarataMD, Natalia Mar @Uromigos @ASCO #GU23
0
16
52
T cell-eosinophil crosstalk—A new road for effective immune checkpoint blockade in breast cancer? https://t.co/r2xL0KBe4s
0
7
20
In a month’s time, we’ve learned that CD8 T cells aren’t the only effectors of immunotherapy response: stealing the show: eosinophils @Cancer_Cell and γδ T cells @Nature out today! @NKI_nl @lab_kok @deVisserKarin @deMirandaLab
https://t.co/Vy32yfG3iU
https://t.co/xr2uniJpGj
6
93
402
1/ Happy to share👇(Tweetorial) our work on T-cell eosinophil crosstalk during immunotherapy response in breast cancer now online @Cancer_Cell A major team-effort lead by Blomberg, Spagnuolo, @hannah_c_garner, @LVoorwerk w/co-senior @deVisserKarin @NKI_nl
5
40
126
Updated table of the latest data for initial IO-based therapy in IMDC Int/Poor mRCC. See thread for discussion of imperfections and thoughts.
4
98
264
We’re having an interactive uromigos meeting in Nashville 30 Sept-1st Oct @DrRanaMcKay @MattGalsky @neerajaiims @DrRosenbergMSK @Prof_Nick_James @montypal @TiansterZhang @shilpaonc @PGrivasMDPhD @Daniel_J_George @kalasri3 details in the podcast https://t.co/SVeV5Kr3Rf…
0
23
50
So proud of my co-fellow @YuWeiChenMD ! Merit Award, YIA, and three posters at #ASCO22 ! Look out Kidney cancer, Dr. Chen is on the scene! @VUMC_Cancer
A busy poster session in the GU section! Congrats to #YuWeiChen #MattTucker @LandonBrownMD for this poster on NER ratio trends on ipi-nivo in metastatic #kidneycancer. #ASCO22
0
1
12
New table highlighting results in IMDC favorable risk RCC across IO-based doublets and nivo/pembro monotx trials. Major caveats about small subsets and differing follow-up, but interesting observations emerge. Thanks to @DrChoueiri and Mike Atkins for help assembling data.
3
78
190
Can artificial intelligence predict outcomes with immunotherapy in NSCLC? Report @JCO_ASCO on an #AI powered spatial analysis of tumor infiltrating lymphocytes (TIL) on whole slide images to define immune phenotypes that correlate to RR and survival. https://t.co/EVmIpm0kPE
ascopubs.org
PURPOSEBiomarkers on the basis of tumor-infiltrating lymphocytes (TIL) are potentially valuable in predicting the effectiveness of immune checkpoint inhibitors (ICI). However, clinical application...
2
17
42
Thanks @oncologytube for the opportunity to discuss the potential role of #ctdna within #SCLC. Shout out to @WadeIams for all his guidance and advocacy for the use of ctdna to guide treatment and improve pt outcomes
Circulating Tumor DNA Dynamics in Relapsed SCLC Christopher Cann, MD @ChrisCannMD @VUMChealth @VUMC_Cancer #IASLC22 #SCLC
https://t.co/bRiSQ0fxHM
2
3
16
Been slow to do this. Congratulations to @VUMCHemOnc @VUMC_Cancer renal team on getting two new Department of Defense Grants to improve our biomarker analyses of renal cell cancer/therapy. @brian_rini @DrScottHaake @KimrynRathmell @katy_beckermann @YuWeiChenMD and Yu Shyr
1
3
26
Dr. Jaime Merchan discusses matching sequencing data with available therapies in RCC and highlights the OPTIC RCC trial lead by Dr. Brian Rini @brian_rini @VUMCHemOnc @VUMC_Cancer @ASCO #GU22
0
3
10
Dr. Sam Chang @UroCancerMD presents the exciting combination of IL-15 agonist (N-803) and BCG in BCG-unresponsive NMIBC @VUMC_Cancer @VUMCurology @ASCO #GU22
2
26
63
Adjuvant Pembrolizumab After Nephrectomy in Renal Cell Carcinoma: Embracing the Promises and Acknowledging the Uncertainties. #ASCODailyNews @ASCO
dailynews.ascopubs.org
The positive interim analysis of the KEYNOTE-564 trial led to the U.S. Food and Drug Administration's (FDA) approval of pembrolizumab in the adjuvant setting for patients with renal cell carcinoma...
2
11
41
Even better than the first! Stay til the end for some high yield solid tumor knowledge! @rmistry91 @vpatelmd @DanielHausrath @TheFellowOnCall
Episode 2 of our Heme/Path Series is now available on @ApplePodcasts, @Spotify, @Google Podcasts, and our website! Can you guess the topic on from the pic below? #MedEd #MedicalEducation #Hematology #Oncology #HemeOnc #Podcast #MedicalStudent #Residency #InternalMedicine #FOAMed
0
3
9
Thanks to everyone who listens and especially the >100 guests who made these happen. @Silke_Gillessen @ChrisSweens1 @AlbigesL @kalasri3 David and Christina.
1
3
33
Congrats @COVID19nCCC! An important paper in @JAMANetwork relevant to #GU: ADT & Mortality In Prostate Cancer & #covid19. Kudos to @shilpaonc @DrRanaMcKay co-seniors, @dr_aschmidt @Tucker_MatthewD co-1st
jamanetwork.com
This cohort study using data from the COVID-19 and Cancer Consortium registry examines whether androgen deprivation therapy is associated with decreased rates of mortality within 30 days of COVID-19...
1
10
31
On our way to building a great support structure for women to excel in #kidneycancer! Thanks to @KimrynRathmell @AlbigesL for leading our inaugural women in #rcc breakfast! #IKCS2021
3
14
63
@brian_rini @TiansterZhang And special thanks to @Brian_Rini, @katy_beckermann , and @TiansterZhang for all the incredible mentorship along the way!! 8/8
0
0
1